DanielRobtBudmanMD

PubMed

• Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715).
  Dyda Dao, Tyler Zemla, Aminah Jatoi, Rachel A. Freedman, Arti Hurria, Hyman B. Muss, Harvey J. Cohen, Lawrence N. Shulman, Marc L. Citron, Daniel R. Budman, Ryan McMur...> ;Oncologist. 2019 Jun 1
• Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.
  Runcie, K., Budman, D. R., John, V., Seetharamu, N.> ;Molecular medicine (Cambridge, Mass.). 2018 Sep 27
• Immune checkpoint inhibitors in lung cancer: an update.
  Sullivan, K. P., Preeshagul, I., Budman, D. R., Seetharamu, N.> ;Future oncology (London, England). 2017 May 10
• 6 citations
  Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
  Kelly-Anne Phillips, Meredith M. Regan, Karin Ribi, Prudence A. Francis, Fabio Puglisi, Meritxell Bellet, Simon Spazzapan, Per Karlsson, Daniel R. Budman, Khalil Zaman...> ;British Journal of Cancer. 2016 Apr 26
• 12 citations
  Immune checkpoint inhibitors in lung cancer: past, present and future.
  Seetharamu, N., Budman, D. R., Sullivan, K. M.> ;Future oncology (London, England). 2016 Mar 30
• Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes.
  Iuliana Shapira, Michaela Oswald, J.L. Lovecchio, Houman Khalili, Andrew W. Menzin, J.S. Whyte, L. Dos Santos, Sharron Liang, Tawfiqul Bhuiya, Mary Keogh, C Mason, Kei...> ;British Journal of Cancer. 2014 Feb 18
• 19 citations
  Profile of panobinostat and its potential for treatment in solid tumors: an update.
  Madhurima Anne, Daniel Sammartino, Myra F. Barginear, Daniel R. Budman> ;OncoTargets and Therapy. 2013 Nov 15
• P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
  Iuliana Shapira, Annette Lee, Reena K. Vora, Daniel R. Budman> ;Critical Reviews in Oncology Hematology. 2013 Nov 1
• 1 citation
  Integrating molecular biology into clinical practice.
  Barginear, M. F., Budman, D. R.> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 May 8
• 8 citations
  The evolving use of arsenic in pharmacotherapy of malignant disease.
  Athena Kritharis, Thomas P. Bradley, Daniel R. Budman> ;Annals of Hematology. 2013 Mar 15
• 3 citations
  Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
  Budman, D. R., Calabro, A., Rosen, L., Lesser, M.> ;Anti-cancer drugs. 2013 Feb 22
• 21 citations
  Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
  Barginear, M. F., John, V., Budman, D. R.> ;Molecular medicine (Cambridge, Mass.). 2012 Dec 1
• 30 citations
  Investigating the Benefit of Adding a Vena Cava Filter to Anticoagulation With Fondaparinux Sodium in Patients With Cancer and Venous Thromboembolism in a Prospective ...
  Myra F. Barginear, Richard J. Gralla, Thomas Bradley, Syed S. Ali, Iuliana Shapira, Craig Greben, Nanette Nier-Shoulson, Meredith Akerman, Martin Lesser, Daniel R. Budman> ;Supportive Care in Cancer. 2012 Mar 16
• Is there an advantage to adding inferior vena cava filter (IVCF) placement to anticoagulation with fondaparinux in patients with cancer and venous thromboemboli (VTE):...
  Barginear MF, Gralla RJ, Akerman M, Lesser M, Bradley TP, Shapira I, Nier-Shoulson NJ, Greben CR, Budman DR> ;J. Clin. Oncol.. 2011-05-20
• Documenting the complete resolution rates of venous thromboemboli (VTE) with the factor Xa inhibitor fondaparinux sodium (FS) in patients with cancer.
  Budman DR, Barginear MF, Gralla RJ, Bradley TP, Shapira I, Nier-Shoulson NJ, Greben CR, Akerman M, Lesser M> ;J. Clin. Oncol.. 2011-05-20
• Association of diabetes mellitus with arsenic trioxide (ATO) evaluated in the treatment of acute promyelocytic leukemia (APL).
  Kritharis A, Bradley TP, Budman DR> ;J. Clin. Oncol.. 2011-05-20
• 17 citations
  Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.
  Mary Leung, David B. Rosen, Scott Fields, Alessandra Cesano, Daniel R Budman> ;Molecular Medicine. 2011 Jan 1
• Emerging role of small ribonucleic acids in gastrointestinal tumors.
  Iuliana Shapira, Keith Sultan, B. Mehrotra, Daniel R. Budman> ;Critical Reviews in Oncology Hematology. 2010 Dec 1
• 12 citations
  The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.
  Budman, D. R., Tai, J., Calabro, A., John, V.> ;Investigational new drugs. 2010 Jun 10
• Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia
  Steven L. Allen, Jonathan E. Kolitz, Ante Sven Lundberg, John M. Bennett, Robert L. Capizzi, Daniel R. Budman> ;Leukemia Research. 2010 Apr 1
• Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cance...
  Lyndsay Harris, Gloria Broadwater, Maysa M. Abu-Khalaf, David Cowan, Ann D. Thor, Daniel R. Budman, Constance Cirrincione, Donald A. Berry, Eric P. Winer, Clifford A. ...> ;Journal of Clinical Oncology. 2009 Jul 20
• Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome.
  Myra F. Barginear, Martin Lesser, Meredith Akerman, Marianna Strakhan, Iuliana Shapira, Thomas Bradley, Daniel R. Budman> ;Clinical and Applied Thrombosis-Hemostasis. 2009 Jun 1
• The hedgehog pathway as a therapeutic target for treatment of breast cancer.
  M. F. Barginear, M. Leung, Daniel R. Budman> ;Breast Cancer Research and Treatment. 2009 May 29
• Determining the preferred dose of the serotonin antagonist (5-HT3) palonosetron: Results of an individual patient data meta-analysis (MA) of 1,947 patients in all rand...
  Lesser M, Gralla R, Napolitano B, Raftopoulos H, Kline M, Bria E, Budman DR> ;J. Clin. Oncol.. 2009-05-20
• Adjuvant chemotherapy for early breast cancer in the elderly.
  Mary Leung, Iulianna Shapira, Thomas Bradley, Daniel R. Budman> ;Current Treatment Options in Oncology. 2009 Apr 10
• Join now to see all